Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease

G. Tzelepis, S. Komanapolli, D. Tyler, D. Vega, A. Fulambarker

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

We assessed the bronchodilating effect of glycopyrrolate (GP) and compared it with that of metaproterenol (MP), alone and in combination (GP+MP), in patients with chronic obstructive pulmonary disease (COPD). In a double-blind study, 11 patients (aged (mean ± SD) 69 ± 6 yrs; forced expiratory volume in one second (FEV1) 1.2 ± 0.4 L) with stable COPD inhaled nebulized GP 1.0 mg, MP 15 mg, or GP 1.0 mg + MP 15 mg. Spirometry was performed before inhalation and at hourly intervals for 8 h after inhalation. It was found that GP produced a bronchodilating effect that was about equal to that of MP but lasted longer (8 vs 5 h). The combination of GP and MP produced a bronchodilating effect that was greater than that of either drug alone and was evident mostly during the effect of MP. The mean peak percentage improvement in FEV1 over baseline was 35% for GP+MP and 25% for either drug alone. These data suggest that nebulized gbcopyrrolate is an effective bronchodilator in some patients with chronic obstructive pulmonary disease. Concurrent administration of glycopyrrolate and metaproterenol produces additional bronchodilation that is primarily apparent during the bronchodilator effect of metaproterenol.

Original languageEnglish (US)
Pages (from-to)100-103
Number of pages4
JournalEuropean Respiratory Journal
Volume9
Issue number1
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Keywords

  • Bronchitis
  • Bronchodilators
  • Glycopyrrolate

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

  • Cite this